focus -WSS

focus

author：Wikipedia 2025-09-27 22:46:07 - browse：4752

Blue Cross Blue Shield website seen on several laptop screens. -- health business coverage from STAT — Adobe

A program that undergirds the Affordable Care Act’s health insurance marketplaces continues to bolster the balance sheets of large Blue Cross Blue Shield companies, according to a STAT analysis of new federal data.

Conversely, that same program — called “risk adjustment” — has created substantial financial burdens for startup insurers including Bright Health Group, which has now exited all health insurance markets, and Friday Health Plans, which has shut down.

More than two dozen BCBS insurers are projected to collect more than $4.7 billion from competing insurers on the ACA marketplaces, according to the analysis. The biggest amounts are concentrated among a few dominant Blues conglomerates.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Will generative AI in health care meet the fate of IBM's Dr. Watson?

WSS

Steward Health Care has deal to sell doctor network to UnitedHealth

Study on Amgen’s bispecific immunotherapy produces positive data

Abortion pill Supreme Court ruling could impact entire drug industry

STAT Summit: The economic case for universal basic health care

The problems with dementia villages

Roche drug slashes death risk in early

hotspot

focus

focus

As demand for Covid shots wanes, Moderna seeks its next success

FDA clears Verve to begin U.S. study of gene

Psychedelics group wrestles with new pharma identity

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Trump demands the U.S. pay no more for drugs than other countries … again

Eliminate the waiting period for sterilization covered by Medicaid

Dobbs anniversary: the lost opportunity of abortion as health care

Roivant's CEO is a star, but biotech's black hole persists

Medical records are filled with copy

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

entertainment

Roivant's CEO is a star, but biotech's black hole persists

J&J lung cancer data amount to new salvo against AstraZeneca

Eliminate the waiting period for sterilization covered by Medicaid

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Questions loom on AstraZeneca cancer drug as safety concerns ebb

entertainment

leisure time

knowledge

hotspot